Received Feb 25, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENACTRA) | SANOFI PASTEUR | UNK | — | OT |
medication error (unintentional) due to missed booster dose of Meningococcal Vaccine with no reported adverse event; Initial information received on 20-Feb-2026 regarding an unsolicited valid non-serious case received from a nurse. This case involves an unknown age and unknown gender patient who had medication error (unintentional) due to missed booster dose of MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA] with no reported adverse event. The patient's past vaccination(s) included MENACTRA in 2020. The patient's past medical history, medical treatment(s) and family history were not provided. At the time of the event, the patient had ongoing Neuromyelitis optica spectrum disorder. On an unknown date, the patient missed a booster dose of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE Solution for injection (lot number, strength, dose and expiry not reported) via unknown route in unknown administration site as prophylactic vaccination which was supposed to be on an unknown date in on Dec-2025 with no reported adverse event (booster dose missed). Information regarding batch number and expiration date corresponding to the one at time of event occurrence was requested. It was reported, "last received Menactra back in 2020, and due for the next dose on Dec2025, but the patient did not receive this vaccine. Nurse asked if there's a 'wiggle room' that the patient might still be covered by her last vaccination. Informed that Menactra has already been discontinued. NP (nurse Practitioner) acknowledged and said that it has already been replaced with MENQUADFI. MIS informed that we do not have information on coverage for missed vaccinations of meningococcal vaccines for patients with Neuromyelitis Optica." Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Neuromyelitis optica